Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 31

Results For "EDS"

1383 News Found

Allergan Aesthetics drives India’s potential in the global aesthetic market
News | August 11, 2024

Allergan Aesthetics drives India’s potential in the global aesthetic market

The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020


Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
News | August 10, 2024

Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr

This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.


AstraZeneca Pharma India achieves 31% revenue growth in Q1 FY25
News | August 09, 2024

AstraZeneca Pharma India achieves 31% revenue growth in Q1 FY25

The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years


Atul Bioscience received EIR from USFDA for Ambernath facility
Drug Approval | August 09, 2024

Atul Bioscience received EIR from USFDA for Ambernath facility

The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations


Aster DM Healthcare launches Pediatric & Geriatric Emergency Departments at Aster MIMS, Calicut
Healthcare | August 07, 2024

Aster DM Healthcare launches Pediatric & Geriatric Emergency Departments at Aster MIMS, Calicut

Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care


Lupin completes  successful Phase 3 trials for Lucentis biosimilar
Biotech | August 06, 2024

Lupin completes successful Phase 3 trials for Lucentis biosimilar

The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU


SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr
News | August 06, 2024

SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr

SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024


Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular study
Diagnostic Center | August 05, 2024

Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular study

Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy


European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion
Drug Approval | August 03, 2024

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion

Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept